Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.956 |
High Similarity |
NPD1455 |
Phase 3 |
0.956 |
High Similarity |
NPD1454 |
Phase 3 |
0.9195 |
High Similarity |
NPD9602 |
Phase 3 |
0.9195 |
High Similarity |
NPD9603 |
Phase 3 |
0.9195 |
High Similarity |
NPD9604 |
Approved |
0.9062 |
High Similarity |
NPD6946 |
Approved |
0.8851 |
High Similarity |
NPD9601 |
Approved |
0.8791 |
High Similarity |
NPD9585 |
Discontinued |
0.8506 |
High Similarity |
NPD9600 |
Approved |
0.8462 |
Intermediate Similarity |
NPD9553 |
Approved |
0.8462 |
Intermediate Similarity |
NPD9554 |
Approved |
0.8462 |
Intermediate Similarity |
NPD301 |
Discontinued |
0.8421 |
Intermediate Similarity |
NPD514 |
Clinical (unspecified phase) |
0.8315 |
Intermediate Similarity |
NPD9572 |
Clinical (unspecified phase) |
0.8286 |
Intermediate Similarity |
NPD3138 |
Phase 3 |
0.828 |
Intermediate Similarity |
NPD267 |
Discontinued |
0.8208 |
Intermediate Similarity |
NPD3139 |
Phase 3 |
0.8202 |
Intermediate Similarity |
NPD9573 |
Phase 2 |
0.8191 |
Intermediate Similarity |
NPD6943 |
Clinical (unspecified phase) |
0.8125 |
Intermediate Similarity |
NPD9639 |
Clinical (unspecified phase) |
0.8021 |
Intermediate Similarity |
NPD215 |
Discontinued |
0.7935 |
Intermediate Similarity |
NPD9555 |
Phase 2 |
0.7865 |
Intermediate Similarity |
NPD9427 |
Approved |
0.7755 |
Intermediate Similarity |
NPD6948 |
Phase 3 |
0.77 |
Intermediate Similarity |
NPD192 |
Phase 2 |
0.7528 |
Intermediate Similarity |
NPD9407 |
Approved |
0.75 |
Intermediate Similarity |
NPD4743 |
Phase 2 |
0.7476 |
Intermediate Similarity |
NPD7651 |
Approved |
0.7474 |
Intermediate Similarity |
NPD9580 |
Clinical (unspecified phase) |
0.7474 |
Intermediate Similarity |
NPD9581 |
Clinical (unspecified phase) |
0.7473 |
Intermediate Similarity |
NPD9403 |
Discontinued |
0.7429 |
Intermediate Similarity |
NPD3128 |
Phase 3 |
0.7407 |
Intermediate Similarity |
NPD1804 |
Phase 2 |
0.7407 |
Intermediate Similarity |
NPD1805 |
Phase 2 |
0.7358 |
Intermediate Similarity |
NPD1428 |
Phase 2 |
0.7358 |
Intermediate Similarity |
NPD3129 |
Phase 3 |
0.7273 |
Intermediate Similarity |
NPD285 |
Discontinued |
0.7204 |
Intermediate Similarity |
NPD9429 |
Discontinued |
0.7191 |
Intermediate Similarity |
NPD9405 |
Approved |
0.7184 |
Intermediate Similarity |
NPD3121 |
Phase 2 |
0.7111 |
Intermediate Similarity |
NPD9653 |
Clinical (unspecified phase) |
0.7018 |
Intermediate Similarity |
NPD6936 |
Clinical (unspecified phase) |
0.7018 |
Intermediate Similarity |
NPD6935 |
Phase 3 |
0.701 |
Intermediate Similarity |
NPD9557 |
Clinical (unspecified phase) |
0.699 |
Remote Similarity |
NPD762 |
Discontinued |
0.6961 |
Remote Similarity |
NPD1706 |
Clinical (unspecified phase) |
0.6916 |
Remote Similarity |
NPD1061 |
Clinical (unspecified phase) |
0.6852 |
Remote Similarity |
NPD2633 |
Phase 1 |
0.6809 |
Remote Similarity |
NPD9372 |
Phase 2 |
0.6759 |
Remote Similarity |
NPD244 |
Clinical (unspecified phase) |
0.67 |
Remote Similarity |
NPD1760 |
Approved |
0.6699 |
Remote Similarity |
NPD1686 |
Approved |
0.6698 |
Remote Similarity |
NPD5789 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD9565 |
Discontinued |
0.6607 |
Remote Similarity |
NPD6693 |
Phase 3 |
0.6598 |
Remote Similarity |
NPD9556 |
Approved |
0.6569 |
Remote Similarity |
NPD755 |
Phase 3 |
0.6538 |
Remote Similarity |
NPD279 |
Clinical (unspecified phase) |
0.6531 |
Remote Similarity |
NPD9560 |
Approved |
0.6531 |
Remote Similarity |
NPD9561 |
Approved |
0.6525 |
Remote Similarity |
NPD6918 |
Phase 1 |
0.6509 |
Remote Similarity |
NPD2621 |
Clinical (unspecified phase) |
0.6481 |
Remote Similarity |
NPD223 |
Clinical (unspecified phase) |
0.6465 |
Remote Similarity |
NPD9559 |
Phase 1 |
0.6465 |
Remote Similarity |
NPD9546 |
Phase 2 |
0.6449 |
Remote Similarity |
NPD502 |
Approved |
0.6429 |
Remote Similarity |
NPD9558 |
Phase 3 |
0.6421 |
Remote Similarity |
NPD9370 |
Approved |
0.64 |
Remote Similarity |
NPD9533 |
Phase 2 |
0.64 |
Remote Similarity |
NPD280 |
Approved |
0.6392 |
Remote Similarity |
NPD9369 |
Clinical (unspecified phase) |
0.6379 |
Remote Similarity |
NPD7914 |
Suspended |
0.6373 |
Remote Similarity |
NPD241 |
Discontinued |
0.6364 |
Remote Similarity |
NPD2691 |
Clinical (unspecified phase) |
0.6275 |
Remote Similarity |
NPD170 |
Approved |
0.6275 |
Remote Similarity |
NPD9562 |
Discovery |
0.6275 |
Remote Similarity |
NPD240 |
Phase 3 |
0.6261 |
Remote Similarity |
NPD284 |
Phase 1 |
0.625 |
Remote Similarity |
NPD3161 |
Clinical (unspecified phase) |
0.6168 |
Remote Similarity |
NPD501 |
Phase 1 |
0.6139 |
Remote Similarity |
NPD9529 |
Phase 1 |
0.6095 |
Remote Similarity |
NPD841 |
Approved |
0.6078 |
Remote Similarity |
NPD238 |
Clinical (unspecified phase) |
0.6078 |
Remote Similarity |
NPD239 |
Phase 2 |
0.604 |
Remote Similarity |
NPD9534 |
Phase 2 |
0.604 |
Remote Similarity |
NPD9535 |
Phase 2 |
0.6 |
Remote Similarity |
NPD1385 |
Discontinued |
0.5981 |
Remote Similarity |
NPD251 |
Approved |
0.5926 |
Remote Similarity |
NPD7761 |
Suspended |
0.5876 |
Remote Similarity |
NPD9347 |
Approved |
0.5876 |
Remote Similarity |
NPD9346 |
Approved |
0.5854 |
Remote Similarity |
NPD7756 |
Clinical (unspecified phase) |
0.5761 |
Remote Similarity |
NPD9211 |
Clinical (unspecified phase) |
0.5714
|
Remote Similarity |
NPD9654 |
Phase 2 |